A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

Dominick J. Angiolillo(University of Florida), Mark B. Effron(Eli Lilly (United States)), Baojin Zhu(Eli Lilly (United States)), Andrew L. Frelinger(University of Nottingham), Brian Baker, J J Badimón(Mount Sinai Hospital), Jorge F. Saucedo, Clement K. Ojeh(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Alan D. Michelson(Harvard University)
European Heart Journal
January 20, 2011
10.1093/eurheartj/ehq494
Cited by 182

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
|The Lancet|2009|723
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651